



March 29, 2024

On behalf of the American Society of Hematology (ASH) and the American Society for Transplantation and Cellular Therapy (ASTCT), and the National Marrow Donor Program (NMDP) we are writing regarding the revised National Coverage Determination (NCD) for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS), which was finalized by the Centers for Medicare & Medicaid Services (CMS) on March 6, 2024. For patients with clinical status and risk scores, some patients already scheduled for HSCT before March 6 had their coverage based on the CED may now experience a coverage shift and could be left without coverage which would have been determined at the federal level and will now be left for adjudication locally.

Thank you for consideration. We would like to offer our societies as resources to you and would be happy to identify subject matter experts or provide the names of hematology Carrier Advisory

Committee representatives, should you need their assistance. We also have resources available that can be provided to you during this period of transition. If you have questions or would like to discuss the revised NCD and other coverage issues, please use Suzanne Leous, ASH Chief Policy Officer ([sleous@hematology.org](mailto:sleous@hematology.org); 202-292-0258), as your point of contact.

Sincerely,

Handwritten signature of Mohandas Narla in black ink.

Mohandas Narla, DSc  
ASH President

Corey Cutler, MD, MPH  
ASTCT President

Amy Ronneberg  
NMDP Chief Executive Officer